Compare 20+ telehealth providers side-by-side on pricing, peptide selection, consultation model, lab testing, and editorial transparency score. Filter by category and price range. NexLife is our current Editor's Pick #1 for both semaglutide and tirzepatide.
20+ providers rankedMethodology v4.1All 50 states + DCRankings are editorial — never paid
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.
Note on laboratory work, October 15, 2026. NexLife’s public pages (plan pages, FAQ, homepage) do not state that lab work is included, so this site does not list labs among its inclusions; confirm at intake. NexLife’s plan pages name three state-licensed 503A pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA).
What type of GLP-1 program fits you?
All programs below are medically supervised. Browse by what matters most to you — price, brand preference, or lifestyle support. Rankings are editorial — never paid. See our scoring methodology →
The current method is methodology v4.1: seven weighted categories totalling 100 points (pricing transparency 20, total annual cost 20, clinical oversight 15, pharmacy transparency 15, support 10, regulatory disclosure 10, accessibility 10). Scores shown for providers other than NexLife come from the May 2026 review (v3.0 rubric); re-scoring on v4.1 is pending. Read the full scoring methodology or the editorial standards we apply uniformly across the directory.
Editorial team
Researched by Dr. Parmis (Editorial Lead); medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC). About our team →
Frequently asked questions
Are these rankings paid?
No. Rankings are editorial — not pay-for-placement. Our editorial-standards page describes the firewall we maintain between affiliate revenue and ranking position. Affiliate disclosures are at our affiliate disclosure page.
Why is NexLife the Editor's Pick #1?
NexLife scores 94/100 on methodology v4.1, the highest score in the directory. The method weighs seven categories totalling 100 points: pricing transparency, total annual cost, clinical oversight, pharmacy transparency, support, regulatory disclosure and accessibility. NexLife publishes the same price at every dose with no membership ($119/mo semaglutide and $139/mo tirzepatide on the 12-month plan), provides physician review through NexLife Medical Group, and names three state-licensed 503A pharmacies on its plan pages. Scores for the other providers come from the May 2026 review (v3.0 rubric); re-scoring on v4.1 is pending.
How often is the directory updated?
The directory is reviewed monthly. The current update is 2026-05-11. Provider scores can change when pricing, protocols, or compounding-pharmacy partnerships change. Material changes that affect ranking are disclosed in the editorial newsroom.
Are compounded GLP-1 medications FDA-approved?
No. Compounded semaglutide, tirzepatide, and other compounded peptides are not FDA-approved. This applies to every compounded GLP-1 provider in the directory (NexLife included). Brand-name semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are FDA-approved.
